Telix Pharmaceuticals Ltd. (TLX, TLPPF,TLX.AX), on Friday announced officially opened Telix Manufacturing Solutions in Yokohama, marking its first cyclotron facility in the Asia-Pacific region.
The site will first support clinical supply of TLX250-CDx, Telix's kidney cancer imaging candidate.
Yokohama Telix will later supply other investigational and future commercial radiopharmaceuticals for the treatment of prostate and brain cancer.
Telix Manufacturing Solutions is a 39-site network enabling Telix to produce and distribute radiopharmaceuticals worldwide, supported by major hubs in Brussels and the U.S. and powered by the company's QIS isotope production technology.
Telix Pharma closed trading 0.72% lesser at AUD 13.78 on the Australian Securities Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.